CCI vs RPRX · P/E 40, rev $2.02B vs P/E 15, rev $1.30B
Crown Castle (CCI) versus Royalty Pharma Plc (RPRX) — a side-by-side from cached financials, not a winner call.
Crown Castle (CCI) is a reit - specialty company listed on US.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Latest reported CCI revenue for 2026-06-30 was $2.02B. Net income was $245.0M. Revenue was up 99.8% from 2026-03-31 to 2026-06-30. CCI currently screens at market cap $40.93B and trailing P/E 39.6.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
CCI currently screens at market cap $40.93B and trailing P/E 39.6. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Not investment advice. Open the CCI and RPRX stock pages for the full models.
Not investment advice.